Similarly, ICC patients with high expression of both CD68 and SIRPα showed a poorer prognosis than patients with high expression of only CD68 or SIRPα and patents with low expression of both CD68 and SIRPα (Fig. 5H,  P < 0.05). Here, SIRPA is linked to intrahepatic cholangiocarcinoma.